 |
|
|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Effective delivery of BNPs™ to the heart after systemic (intravenous) injection and the therapeutic benefits of DNA-based protein Phosphatase-1 Inhibitor-1 (I-1) delivery to the failing heart have been demonstrated in several proof-of-principle animal studies. NanoCor has also conducted several failing heart pig studies which demonstrate the therapeutic benefits of I-1 with recombinant adeno-associated virus (rAAV) and the Self-Complementary Vector. The Company is currently conducting several failing heart pig studies with several different candidates of heart tropic BNPs™ to determine the best candidate to advance into human clinical trials. BNPs™ were used by Asklêpios BioPharmaceutical in a Phase I clinical trial for the treatment of Duchene’s Muscular Dystrophy (DMD), an orphan disease affecting children for which there is currently no life-sustaining treatment. The self-complementary AAV vector technology used by NanoCor has been validated in a human hemophilia clinical trial demonstrating 100 of sustained therapeutic of factor IX. |
||||
| About Nanocor | ||||
|
|
||||
| Contact Us | ||||
|
||||
870 Martin Luther King Jr. Blvd.
NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a minimal-invasive treatment for these patients and advance the current standard of care.